Metastatic Prostate Carcinoma Clinical Trials

78 clinical trials for Metastatic Prostate Carcinoma across international registries, including 13 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer — RECRUITING
• Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging — RECRUITING · PHASE3
• Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy — RECRUITING · PHASE1
• Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients — RECRUITING · PHASE1
• Extending Prostate Genetic Awareness, Navigation, and Delivery: The EXPAND Network — RECRUITING
• Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial — RECRUITING · NA
• Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation — RECRUITING · NA
• FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial — RECRUITING · PHASE2
• Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer — RECRUITING · PHASE2
• Access to Genetic Testing in Underserved Patients With Cancer — RECRUITING · NA
• Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial — RECRUITING · NA
• PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer — RECRUITING · PHASE1
• Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy — RECRUITING · PHASE2
• Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy — COMPLETED
• Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations — ACTIVE_NOT_RECRUITING · PHASE2
• Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer — COMPLETED · PHASE3
• Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects — ACTIVE_NOT_RECRUITING · PHASE2
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV — ACTIVE_NOT_RECRUITING · PHASE1
• DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers — ACTIVE_NOT_RECRUITING · PHASE1
• 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer — TERMINATED · PHASE2
• National Cancer Institute "Cancer Moonshot Biobank" — ACTIVE_NOT_RECRUITING
• Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer — COMPLETED · PHASE1
• Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery — COMPLETED · PHASE1
• Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression — TERMINATED · PHASE1
• Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE4
• Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM) — ACTIVE_NOT_RECRUITING · PHASE2
• Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study — COMPLETED · NA
• Genetic Testing for Men With Metastatic Prostate Cancer — TERMINATED
• 68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer — COMPLETED · PHASE3
• Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer — COMPLETED · PHASE2
• 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression — TERMINATED · PHASE1
• Resistance Training +/- Creatine for Metastatic Prostate Cancer Patients — COMPLETED · PHASE1
• 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer — COMPLETED · PHASE1
• An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic Response in Patients With Metastatic Prostate Cancer — TERMINATED · PHASE4
• Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone — COMPLETED · PHASE2
• ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer — TERMINATED · PHASE2
• Gallium-68 PSMA-11 PET in Participants With Prostate Cancer — WITHDRAWN · PHASE2
• Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer — OTHER · PHASE1
• Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer — TERMINATED · PHASE2

Refine this search